Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.
2.

Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Grayston JT, Belland RJ, Byrne GI, Kuo CC, Schachter J, Stamm WE, Zhong G.

Pathog Dis. 2015 Feb;73(1):1-9. doi: 10.1093/femspd/ftu015. Epub 2014 Dec 4. Review. No abstract available.

3.

Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist.

Patil R, Szabó E, Fells JI, Balogh A, Lim KG, Fujiwara Y, Norman DD, Lee SC, Balazs L, Thomas F, Patil S, Emmons-Thompson K, Boler A, Strobos J, McCool SW, Yates CR, Stabenow J, Byrne GI, Miller DD, Tigyi GJ.

Chem Biol. 2015 Feb 19;22(2):206-16. doi: 10.1016/j.chembiol.2014.12.009. Epub 2015 Jan 22.

4.

Analysis of CPAF mutants: new functions, new questions (the ins and outs of a chlamydial protease).

Bavoil PM, Byrne GI.

Pathog Dis. 2014 Aug;71(3):287-91. doi: 10.1111/2049-632X.12194.

5.

Chlamydia exploit the mammalian tryptophan-depletion defense strategy as a counter-defensive cue to trigger a survival state of persistence.

Bonner CA, Byrne GI, Jensen RA.

Front Cell Infect Microbiol. 2014 Feb 28;4:17. doi: 10.3389/fcimb.2014.00017. eCollection 2014. Review.

6.

Genetic variation in Chlamydia trachomatis and their hosts: impact on disease severity and tissue tropism.

Abdelsamed H, Peters J, Byrne GI.

Future Microbiol. 2013 Sep;8(9):1129-1146. doi: 10.2217/fmb.13.80. Review.

7.

The Chlamydia trachomatis CT149 protein exhibits esterase activity in vitro and catalyzes cholesteryl ester hydrolysis when expressed in HeLa cells.

Peters J, Onguri V, Nishimoto SK, Marion TN, Byrne GI.

Microbes Infect. 2012 Nov;14(13):1196-204. doi: 10.1016/j.micinf.2012.07.020. Epub 2012 Aug 23.

8.

Host genetics and Chlamydia disease: prediction and validation of disease severity mechanisms.

Miyairi I, Ziebarth J, Laxton JD, Wang X, van Rooijen N, Williams RW, Lu L, Byrne GI, Cui Y.

PLoS One. 2012;7(3):e33781. doi: 10.1371/journal.pone.0033781. Epub 2012 Mar 16.

9.

Chlamydia psittaci genetic variants differ in virulence by modulation of host immunity.

Miyairi I, Laxton JD, Wang X, Obert CA, Arva Tatireddigari VR, van Rooijen N, Hatch TP, Byrne GI.

J Infect Dis. 2011 Aug 15;204(4):654-63. doi: 10.1093/infdis/jir333.

10.

Summary: The natural history and immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia control.

Gottlieb SL, Martin DH, Xu F, Byrne GI, Brunham RC.

J Infect Dis. 2010 Jun 15;201 Suppl 2:S190-204.

PMID:
20524236
11.

Chlamydia trachomatis strains and virulence: rethinking links to infection prevalence and disease severity.

Byrne GI.

J Infect Dis. 2010 Jun 15;201 Suppl 2:S126-33. doi: 10.1086/652398. Review.

12.

Introduction: The natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control.

Gottlieb SL, Brunham RC, Byrne GI, Martin DH, Xu F, Berman SM.

J Infect Dis. 2010 Jun 15;201 Suppl 2:S85-7. doi: 10.1086/652392. No abstract available.

PMID:
20470045
13.

The p47 GTPases Iigp2 and Irgb10 regulate innate immunity and inflammation to murine Chlamydia psittaci infection.

Miyairi I, Tatireddigari VR, Mahdi OS, Rose LA, Belland RJ, Lu L, Williams RW, Byrne GI.

J Immunol. 2007 Aug 1;179(3):1814-24.

14.

Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2.

Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI.

Infect Immun. 2007 Feb;75(2):753-9. Epub 2006 Dec 4.

15.

Global transcriptional upregulation in the absence of increased translation in Chlamydia during IFNgamma-mediated host cell tryptophan starvation.

Ouellette SP, Hatch TP, AbdelRahman YM, Rose LA, Belland RJ, Byrne GI.

Mol Microbiol. 2006 Dec;62(5):1387-401. Epub 2006 Oct 24.

16.

Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma.

Hahn DL, Plane MB, Mahdi OS, Byrne GI.

PLoS Clin Trials. 2006 Jun;1(2):e11. Epub 2006 Jun 30.

17.

Different growth rates of Chlamydia trachomatis biovars reflect pathotype.

Miyairi I, Mahdi OS, Ouellette SP, Belland RJ, Byrne GI.

J Infect Dis. 2006 Aug 1;194(3):350-7. Epub 2006 Jun 22.

PMID:
16826483
18.

Chlamydia and programmed cell death.

Miyairi I, Byrne GI.

Curr Opin Microbiol. 2006 Feb;9(1):102-8. Epub 2006 Jan 9. Review.

PMID:
16406838
19.

The Chlamydia pneumoniae type III secretion-related lcrH gene clusters are developmentally expressed operons.

Ouellette SP, Abdelrahman YM, Belland RJ, Byrne GI.

J Bacteriol. 2005 Nov;187(22):7853-6.

20.

Chlamydia and apoptosis: life and death decisions of an intracellular pathogen.

Byrne GI, Ojcius DM.

Nat Rev Microbiol. 2004 Oct;2(10):802-8. Review.

PMID:
15378044
21.

Chlamydia.

Belland R, Ojcius DM, Byrne GI.

Nat Rev Microbiol. 2004 Jul;2(7):530-1. doi: 10.1038/nrmicro931. No abstract available.

PMID:
15248311
22.

Chlamydia pneumoniae and atherosclerosis.

Belland RJ, Ouellette SP, Gieffers J, Byrne GI.

Cell Microbiol. 2004 Feb;6(2):117-27. Review.

PMID:
14706098
23.

Inducible nitric oxide synthase regulates production of isoprostanes in vivo during chlamydial genital infection in mice.

Ramsey KH, Sigar IM, Rana SV, Gupta J, Holland SM, Byrne GI, Morrow JD.

Infect Immun. 2003 Dec;71(12):7183-7.

24.

Genotypic differences in the Chlamydia pneumoniae tyrP locus related to vascular tropism and pathogenicity.

Gieffers J, Durling L, Ouellette SP, Rupp J, Maass M, Byrne GI, Caldwell HD, Belland RJ.

J Infect Dis. 2003 Oct 15;188(8):1085-93. Epub 2003 Oct 10.

PMID:
14551876
25.

Chlamydia uncloaked.

Byrne GI.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8040-2. Epub 2003 Jun 30. No abstract available.

26.

Serological association between Chlamydia pneumoniae infection and age-related macular degeneration.

Kalayoglu MV, Galvan C, Mahdi OS, Byrne GI, Mansour S.

Arch Ophthalmol. 2003 Apr;121(4):478-82.

PMID:
12695244
27.

Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease.

Kalayoglu MV, Libby P, Byrne GI.

JAMA. 2002 Dec 4;288(21):2724-31. Review.

PMID:
12460096
28.
29.

Isolation of Chlamydia pneumoniae clonal variants by a focus-forming assay.

Gieffers J, Belland RJ, Whitmire W, Ouellette S, Crane D, Maass M, Byrne GI, Caldwell HD.

Infect Immun. 2002 Oct;70(10):5827-34.

31.

Chlamydia pneumoniae as a respiratory pathogen.

Hahn DL, Azenabor AA, Beatty WL, Byrne GI.

Front Biosci. 2002 Mar 1;7:e66-76. Review.

PMID:
11861211
32.

Chlamydial treatment failures: a persistent problem?

Byrne GI.

J Eur Acad Dermatol Venereol. 2001 Sep;15(5):381. No abstract available.

PMID:
11763371
33.
34.

Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells.

Kalayoglu MV, Perkins BN, Byrne GI.

Microbes Infect. 2001 Oct;3(12):963-9.

PMID:
11580983
35.

The challenge of defining disease.

Byrne GI.

Science. 2001 Sep 7;293(5536):1765-6. No abstract available.

PMID:
11556363
36.

Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells.

Byrne GI, Ouellette SP, Wang Z, Rao JP, Lu L, Beatty WL, Hudson AP.

Infect Immun. 2001 Sep;69(9):5423-9.

37.

Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome.

Ramsey KH, Miranpuri GS, Sigar IM, Ouellette S, Byrne GI.

Infect Immun. 2001 Aug;69(8):5131-7.

38.

Collaborative multidisciplinary workshop report: interface of lipid metabolism, atherosclerosis, and Chlamydia infection.

Byrne GI, Skarlotos SI, Grunfeld C, Kalayoglu MV, Libby P, Saikku P, Summersgill JT, Wyrick P.

J Infect Dis. 2000 Jun;181 Suppl 3:S490-1. No abstract available.

PMID:
10839745
39.

Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions.

Kalayoglu MV, Indrawati, Morrison RP, Morrison SG, Yuan Y, Byrne GI.

J Infect Dis. 2000 Jun;181 Suppl 3:S483-9. Review.

PMID:
10839744
40.

Reply

Kalayoglu MV, Myint M, Byrne GI.

J Infect Dis. 2000 May;181(5):1869-70. No abstract available.

PMID:
10823810
41.

Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae.

Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI.

Microbes Infect. 1999 May;1(6):409-18.

PMID:
10602673
42.

Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease.

LaVerda D, Albanese LN, Ruther PE, Morrison SG, Morrison RP, Ault KA, Byrne GI.

Infect Immun. 2000 Jan;68(1):303-9.

43.

Chlamydia pneumoniae and atherosclerosis: links to the disease process.

Byrne GI, Kalayoglu MV.

Am Heart J. 1999 Nov;138(5 Pt 2):S488-90.

PMID:
10539855
44.

Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae.

Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI.

J Infect Dis. 1999 Sep;180(3):780-90.

PMID:
10438367
45.

Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection.

Ramsey KH, Cotter TW, Salyer RD, Miranpuri GS, Yanez MA, Poulsen CE, DeWolfe JL, Byrne GI.

Infect Immun. 1999 Jun;67(6):3019-25.

46.

Chlamydial heat shock proteins and disease pathology: new paradigms for old problems?

LaVerda D, Kalayoglu MV, Byrne GI.

Infect Dis Obstet Gynecol. 1999;7(1-2):64-71. Review.

48.
50.

Induction of macrophage foam cell formation by Chlamydia pneumoniae.

Kalayoglu MV, Byrne GI.

J Infect Dis. 1998 Mar;177(3):725-9.

PMID:
9498454

Supplemental Content

Loading ...
Support Center